371 related articles for article (PubMed ID: 23047061)
1. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme.
Zhang G; Huang S; Wang Z
J Clin Neurosci; 2012 Dec; 19(12):1636-40. PubMed ID: 23047061
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
Møller S; Grunnet K; Hansen S; Schultz H; Holmberg M; Sorensen M; Poulsen HS; Lassen U
Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
Vredenburgh JJ; Desjardins A; Herndon JE; Marcello J; Reardon DA; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Sampson J; Wagner M; Bailey L; Bigner DD; Friedman AH; Friedman HS
J Clin Oncol; 2007 Oct; 25(30):4722-9. PubMed ID: 17947719
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.
Hasselbalch B; Lassen U; Hansen S; Holmberg M; Sørensen M; Kosteljanetz M; Broholm H; Stockhausen MT; Poulsen HS
Neuro Oncol; 2010 May; 12(5):508-16. PubMed ID: 20406901
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
Hofland KF; Hansen S; Sorensen M; Engelholm S; Schultz HP; Muhic A; Grunnet K; Ask A; Costa JC; Kristiansen C; Thomsen C; Poulsen HS; Lassen U
Acta Oncol; 2014 Jul; 53(7):939-44. PubMed ID: 24456504
[TBL] [Abstract][Full Text] [Related]
6. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab: a treatment option for recurrent glioblastoma multiforme.
Buie LW; Valgus J
Ann Pharmacother; 2008 Oct; 42(10):1486-90. PubMed ID: 18765835
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
Reardon DA; Desjardins A; Peters KB; Vredenburgh JJ; Gururangan S; Sampson JH; McLendon RE; Herndon JE; Coan A; Threatt S; Friedman AH; Friedman HS
Cancer; 2011 Dec; 117(23):5351-8. PubMed ID: 21590689
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
Friedman HS; Prados MD; Wen PY; Mikkelsen T; Schiff D; Abrey LE; Yung WK; Paleologos N; Nicholas MK; Jensen R; Vredenburgh J; Huang J; Zheng M; Cloughesy T
J Clin Oncol; 2009 Oct; 27(28):4733-40. PubMed ID: 19720927
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.
Reardon DA; Desjardins A; Peters KB; Gururangan S; Sampson JH; McLendon RE; Herndon JE; Bulusu A; Threatt S; Friedman AH; Vredenburgh JJ; Friedman HS
J Neurooncol; 2012 Mar; 107(1):155-64. PubMed ID: 21986722
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
Kreisl TN; Kim L; Moore K; Duic P; Royce C; Stroud I; Garren N; Mackey M; Butman JA; Camphausen K; Park J; Albert PS; Fine HA
J Clin Oncol; 2009 Feb; 27(5):740-5. PubMed ID: 19114704
[TBL] [Abstract][Full Text] [Related]
12. A retrospective observational analysis to evaluate the off-label use of bevacizumab alone or with irinotecan in recurrent glioblastoma.
Cecchi M; Vaiani M; Ceroti M; Banfi R
Int J Clin Pharm; 2013 Jun; 35(3):483-7. PubMed ID: 23536107
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab plus irinotecan in recurrent glioblastoma.
Chamberlain MC
J Clin Oncol; 2008 Feb; 26(6):1012-3; author reply 1013. PubMed ID: 18281677
[No Abstract] [Full Text] [Related]
15. Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).
Gil MJ; de Las Peñas R; Reynés G; Balañá C; Peréz-Segura P; García-Velasco A; Mesia C; Gallego O; Fernández-Chacón C; Martínez-García M; Herrero A; Andrés R; Benavides M; Quintanar T; Pérez-Martin X
Anticancer Drugs; 2012 Jul; 23(6):659-65. PubMed ID: 22634799
[TBL] [Abstract][Full Text] [Related]
16. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors.
Bokstein F; Shpigel S; Blumenthal DT
Cancer; 2008 May; 112(10):2267-73. PubMed ID: 18327820
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan.
Urup T; Dahlrot RH; Grunnet K; Christensen IJ; Michaelsen SR; Toft A; Larsen VA; Broholm H; Kosteljanetz M; Hansen S; Poulsen HS; Lassen U
Acta Oncol; 2016; 55(4):418-22. PubMed ID: 26828563
[TBL] [Abstract][Full Text] [Related]
18. [An evaluation of fatigue in patients with glioblastoma relapse treated with the combination of irinotecan-bevacizumab].
Dehais C; Souvannavong V; Nguyen BK; Jouniaux-Delbez N; Golmard JL; Tadrist C; Liou A; Delattre JY
Rev Neurol (Paris); 2011 Nov; 167(11):841-6. PubMed ID: 21514945
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.
Poulsen HS; Grunnet K; Sorensen M; Olsen P; Hasselbalch B; Nelausen K; Kosteljanetz M; Lassen U
Acta Oncol; 2009; 48(1):52-8. PubMed ID: 19031176
[TBL] [Abstract][Full Text] [Related]
20. [Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
Vauleon E; Mesbah H; Gedouin D; Lecouillard I; Louvel G; Hamlat A; Riffaud L; Carsin B; Quillien V; Audrain O; Lesimple T
Bull Cancer; 2012 Feb; 99(2):121-6. PubMed ID: 22257744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]